miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages

Clinical relevance of miRNAs as biomarkers is growing due to their stability and detection in biofluids. In this, diagnosis at asymptomatic stages of Alzheimer's disease (AD) remains a challenge since it can only be made at autopsy according to Braak NFT staging. Achieving the objective of dete...

Descripción completa

Detalles Bibliográficos
Autores: Jácome, Dayaneth, Cotrufo, Tiziana, Andrés Benito, Pol, Lidón Gil, Laia, Martí Puig, Eulàlia, Ferrer, Isidro (Ferrer Abizanda), Río Fernández, José Antonio del, Gavín Marín, Rosalina
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/212266
Acceso en línea:https://hdl.handle.net/2445/212266
Access Level:acceso abierto
Palabra clave:Micro RNAs
Malaltia d'Alzheimer
Indicadors biològics
MicroRNAs
Alzheimer's disease
Indicators (Biology)
id ES_b8bbd091b06195df5a846f6f0332c19b
oai_identifier_str oai:recercat.cat:2445/212266
network_acronym_str ES
network_name_str España
repository_id_str
spelling miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stagesJácome, DayanethCotrufo, TizianaAndrés Benito, PolLidón Gil, LaiaMartí Puig, EulàliaFerrer, Isidro (Ferrer Abizanda)Río Fernández, José Antonio delGavín Marín, RosalinaMicro RNAsMalaltia d'AlzheimerIndicadors biològicsMicroRNAsAlzheimer's diseaseIndicators (Biology)Clinical relevance of miRNAs as biomarkers is growing due to their stability and detection in biofluids. In this, diagnosis at asymptomatic stages of Alzheimer's disease (AD) remains a challenge since it can only be made at autopsy according to Braak NFT staging. Achieving the objective of detecting AD at early stages would allow possible therapies to be addressed before the onset of cognitive impairment. Many studies have determined that the expression pattern of some miRNAs is dysregulated in AD patients, but to date, none has been correlated with downregulated expression of cellular prion protein (PrPC) during disease progression. That is why, by means of cross studies of miRNAs up-regulated in AD with in silico identification of potential miRNAs-binding to 3'UTR of human PRNP gene, we selected miR-519a-3p for our study. Then, in vitro experiments were carried out in two ways. First, we validated miR-519a-3p target on 3'UTR-PRNP, and second, we analyzed the levels of PrPC expression after using of mimic technology on cell culture. In addition, RT-qPCR was performed to analyzed miR-519a-3p expression in human cerebral samples of AD at different stages of disease evolution. Additionally, samples of other neurodegenerative diseases such as other non-AD tauopathies and several synucleinopathies were included in the study. Our results showed that miR-519a-3p overlaps with PRNP 3'UTR in vitro and promotes downregulation of PrPC. Moreover, miR-519a-3p was found to be up-regulated exclusively in AD samples from stage I to VI, suggesting its potential use as a novel label of preclinical stages of the disease.Elsevier B.V.2024202420242024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion8 p.application/pdfhttps://hdl.handle.net/2445/212266Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1016/j.bbadis.2024.167187Biochimica et Biophysica Acta-Molecular Basis of Disease, 2024, vol. 1870, num.5https://doi.org/10.1016/j.bbadis.2024.167187cc-by-nc (c) Jácome, Dayaneth et al., 2024http://creativecommons.org/licenses/by-nc/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2122662026-05-29T05:05:01Z
dc.title.none.fl_str_mv miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages
title miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages
spellingShingle miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages
Jácome, Dayaneth
Micro RNAs
Malaltia d'Alzheimer
Indicadors biològics
MicroRNAs
Alzheimer's disease
Indicators (Biology)
title_short miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages
title_full miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages
title_fullStr miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages
title_full_unstemmed miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages
title_sort miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages
dc.creator.none.fl_str_mv Jácome, Dayaneth
Cotrufo, Tiziana
Andrés Benito, Pol
Lidón Gil, Laia
Martí Puig, Eulàlia
Ferrer, Isidro (Ferrer Abizanda)
Río Fernández, José Antonio del
Gavín Marín, Rosalina
author Jácome, Dayaneth
author_facet Jácome, Dayaneth
Cotrufo, Tiziana
Andrés Benito, Pol
Lidón Gil, Laia
Martí Puig, Eulàlia
Ferrer, Isidro (Ferrer Abizanda)
Río Fernández, José Antonio del
Gavín Marín, Rosalina
author_role author
author2 Cotrufo, Tiziana
Andrés Benito, Pol
Lidón Gil, Laia
Martí Puig, Eulàlia
Ferrer, Isidro (Ferrer Abizanda)
Río Fernández, José Antonio del
Gavín Marín, Rosalina
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Micro RNAs
Malaltia d'Alzheimer
Indicadors biològics
MicroRNAs
Alzheimer's disease
Indicators (Biology)
topic Micro RNAs
Malaltia d'Alzheimer
Indicadors biològics
MicroRNAs
Alzheimer's disease
Indicators (Biology)
description Clinical relevance of miRNAs as biomarkers is growing due to their stability and detection in biofluids. In this, diagnosis at asymptomatic stages of Alzheimer's disease (AD) remains a challenge since it can only be made at autopsy according to Braak NFT staging. Achieving the objective of detecting AD at early stages would allow possible therapies to be addressed before the onset of cognitive impairment. Many studies have determined that the expression pattern of some miRNAs is dysregulated in AD patients, but to date, none has been correlated with downregulated expression of cellular prion protein (PrPC) during disease progression. That is why, by means of cross studies of miRNAs up-regulated in AD with in silico identification of potential miRNAs-binding to 3'UTR of human PRNP gene, we selected miR-519a-3p for our study. Then, in vitro experiments were carried out in two ways. First, we validated miR-519a-3p target on 3'UTR-PRNP, and second, we analyzed the levels of PrPC expression after using of mimic technology on cell culture. In addition, RT-qPCR was performed to analyzed miR-519a-3p expression in human cerebral samples of AD at different stages of disease evolution. Additionally, samples of other neurodegenerative diseases such as other non-AD tauopathies and several synucleinopathies were included in the study. Our results showed that miR-519a-3p overlaps with PRNP 3'UTR in vitro and promotes downregulation of PrPC. Moreover, miR-519a-3p was found to be up-regulated exclusively in AD samples from stage I to VI, suggesting its potential use as a novel label of preclinical stages of the disease.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/212266
url https://hdl.handle.net/2445/212266
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1016/j.bbadis.2024.167187
Biochimica et Biophysica Acta-Molecular Basis of Disease, 2024, vol. 1870, num.5
https://doi.org/10.1016/j.bbadis.2024.167187
dc.rights.none.fl_str_mv cc-by-nc (c) Jácome, Dayaneth et al., 2024
http://creativecommons.org/licenses/by-nc/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc (c) Jácome, Dayaneth et al., 2024
http://creativecommons.org/licenses/by-nc/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 8 p.
application/pdf
dc.publisher.none.fl_str_mv Elsevier B.V.
publisher.none.fl_str_mv Elsevier B.V.
dc.source.none.fl_str_mv Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417674663002112
score 15,811543

Similares en LA Referencia